April 2, 2019 / 5:19 AM / 2 months ago

BRIEF-Novartis' Cosentyx Approved In China For Psoriasis Patients

April 2 (Reuters) - Novartis AG:

* NOVARTIS FIRST-IN-CLASS COSENTYX® APPROVED IN CHINA FOR PSORIASIS PATIENTS

* PHASE III STUDY IN PATIENTS IN CHINA WITH PSORIASIS CONFIRMED A SUSTAINED SAFETY PROFILE AND RAPID ONSET OF RELIEF WITH COSENTYX AS EARLY AS WEEK 3 Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below